Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Research — Stock-based compensation expense by Year
Research — Stock-based compensation expense ($M) ($M)
Vertex Pharmaceuticals Research — Stock-based compensation expense: $94.8M in FY2025, down 15.4% from a year earlier.
Where the FY2025 figure comes from
“|| Stock-based compensation expense | 94.8 | (15)% | 112.1 | 21% | 92.4”
Source: Form 10-K (vrtx-20251231.htm, filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K MD&A (Research Expenses Disaggregation Table).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Vertex Pharmaceuticals Research — Stock-based compensation expense ($M), annual FY2013–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/rd-res-sbc
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.